Table 1. Baseline Characteristics for NSCLC by EGFR-TKIs.
| EGFR-TKIs | P-value | ||||||
|---|---|---|---|---|---|---|---|
| Gefitinib | Erlotinib | Afatinib | |||||
| n | (%) | n | (%) | n | (%) | ||
| Total | 304 | 63 | 81 | ||||
| Sex | 0.213 | ||||||
| Men | 114 | (37.5) | 24 | (38.1) | 39 | (48.1) | |
| Women | 190 | (62.5) | 39 | (61.9) | 42 | (51.9) | |
| Age (years) | 0.095 | ||||||
| < 65 | 154 | (50.7) | 34 | (54.0) | 52 | (64.2) | |
| ≥ 65 | 150 | (49.3) | 29 | (46.0) | 29 | (35.8) | |
| Mean (range) | 65 | (33–93) | 67 | (47–90) | 64 | (37–83) | 0.191 |
| Smoking | 0.802 | ||||||
| Never | 226 | (74.3) | 48 | (76.2) | 63 | (77.8) | |
| Current or ever | 78 | (25.7) | 15 | (23.8) | 18 | (22.2) | |
| Clinical stage | 0.449 | ||||||
| IIIb | 16 | (5.3) | 5 | (7.9) | 7 | (8.6) | |
| IV | 288 | (94.7) | 58 | (92.1) | 74 | (91.4) | |
| EGFR mutation | 0.119 | ||||||
| Del19 | 148 | (48.7) | 27 | (42.9) | 48 | (59.3) | |
| L858R | 156 | (51.3) | 36 | (57.1) | 33 | (40.7) | |
| Baseline brain metastases | 0.867 | ||||||
| Absence | 244 | (80.3) | 52 | (82.5) | 64 | (79.0) | |
| Presence | 60 | (19.7) | 11 | (17.5) | 17 | (21.0) | |
| ECOG PS | 0.017 | ||||||
| 0 & 1 | 231 | (76.0) | 56 | (88.9) | 70 | (86.4) | |
| > 1 | 73 | (24.0) | 7 | (11.1) | 11 | (13.6) | |
| Grade | 0.139 | ||||||
| 1 | 59 | (19.4) | 12 | (19.4) | 25 | (30.9) | |
| 2 | 64 | (21.1) | 19 | (30.2) | 21 | (25.9) | |
| 3 | 49 | (16.1) | 9 | (14.3) | 9 | (11.1) | |
| missing | 132 | (43.4) | 23 | (36.5) | 26 | (32.1) | |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.